Health care

REVEAL GENOMICS® HER2DX® Genomic Test to Undergo First Prospective Trial as Part of the DEFINITIVE Project, Funded by the European Commission

Retrieved on: 
Wednesday, February 28, 2024

The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.

Key Points: 
  • The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.
  • As a collaborating partner in this study, REVEAL GENOMICS® is committed to generating robust evidence designed to influence and evolve standard clinical practices.
  • We are immensely grateful to all our partners and the multidisciplinary team participating in this trial.
  • The DEFINITIVE trial seeks to assess the clinical efficacy of HER2DX® by comparing the outcomes of patients who undergo the genomic test with those who do not.

SecurityScorecard Third-Party Breach Report Reveals Software Supply Chain as Top Target for Ransomware Groups

Retrieved on: 
Wednesday, February 28, 2024

Using the world’s largest proprietary risk and threat data set, SecurityScorecard STRIKE threat hunters analyzed threat groups’ mass exploitation of supply chain vulnerabilities.

Key Points: 
  • Using the world’s largest proprietary risk and threat data set, SecurityScorecard STRIKE threat hunters analyzed threat groups’ mass exploitation of supply chain vulnerabilities.
  • View the full release here: https://www.businesswire.com/news/home/20240228143611/en/
    Technology supply chain vulnerabilities enable threat actors to scale their operations with minimal effort.
  • With BreachDetails, SecurityScorecard increased the level of breach data coverage by 50% compared to other breach notice providers by using AI to analyze news articles, ransomware notifications, and international sources.
  • Ryan Sherstobitoff, Senior Vice President of Threat Research and Intelligence, SecurityScorecard, said:
    “The supplier ecosystem is a highly desirable target for ransomware groups.

The MolinaCares Accord Invests $3.7 Million to Improve Health Equity in Illinois

Retrieved on: 
Wednesday, February 28, 2024

Molina Healthcare of Illinois (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), is announcing a $3.7 million investment in the MolinaCares Illinois Health Equity Initiative.

Key Points: 
  • Molina Healthcare of Illinois (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), is announcing a $3.7 million investment in the MolinaCares Illinois Health Equity Initiative.
  • In total, Molina has dedicated approximately $5 million to improve equity in health outcomes for under-resourced communities in Illinois.
  • “As part of our commitment to advancing health equity, Molina is deploying a multi-pronged approach that targets various areas of health care, working alongside community-based organizations and providers,” said Matthew Wolf, plan president of Molina Healthcare of Illinois.
  • Studies have shown those who live in poverty tend to have a higher disease burden, according to the National Health Council .

Simplify Healthcare and Forge Join Forces to Elevate the Document Generation Experience for Payers

Retrieved on: 
Tuesday, February 27, 2024

This partnership combines Simplify Healthcare’s expertise in benefit plan management and generation of associated documents and Forge’s dynamic digital document factory to provide Healthcare Payers with an Integrated Document Generation Experience that helps them seamlessly generate, print, and ship high-quality communication materials to groups, members, and employers.

Key Points: 
  • This partnership combines Simplify Healthcare’s expertise in benefit plan management and generation of associated documents and Forge’s dynamic digital document factory to provide Healthcare Payers with an Integrated Document Generation Experience that helps them seamlessly generate, print, and ship high-quality communication materials to groups, members, and employers.
  • Simplify Healthcare will be at the forefront, empowered by Forge's cutting-edge technology to streamline document generation, personalize member touchpoints, and optimize costs.
  • — Bhaumik Kothari , Vice President, Strategic Partnerships, Simplify Healthcare
    “We are excited about the strategic partnership with Simplify Healthcare.
  • Together, we are forging a path to elevate the standards in healthcare technology solutions.” — Jason Fonner , Vice President, Forge

Huron Announces Fourth Quarter and Record Full Year 2023 Financial Results, Increases Borrowing Capacity with $275 Million Term Loan, and Provides 2024 Guidance

Retrieved on: 
Tuesday, February 27, 2024

The number of revenue-generating professionals(2) increased 14.2% to 5,519 as of December 31, 2023 from 4,832 as of December 31, 2022.

Key Points: 
  • The number of revenue-generating professionals(2) increased 14.2% to 5,519 as of December 31, 2023 from 4,832 as of December 31, 2022.
  • The utilization rate(6) of the company's Digital capability increased to 75.3% for full year 2023, compared to 71.0% for full year 2022.
  • Additionally, in 2023, Huron repurchased 1,461,815 shares of the company's common stock for $123.6 million, representing 7.4% of our common stock outstanding as of December 31, 2022.
  • Management has not reconciled these non-GAAP financial measures to the corresponding GAAP financial measures because guidance for the various reconciling items is not provided.

AlertMedia Named Customers’ Choice in 2024 Gartner Peer Insights™ Voice of the Customer for Emergency/Mass Notification Services Solutions Report

Retrieved on: 
Tuesday, February 27, 2024

Reviews from AlertMedia customers have noted the platform’s ease of use, the rapid speed of implementation, and exceptional customer service.

Key Points: 
  • Reviews from AlertMedia customers have noted the platform’s ease of use, the rapid speed of implementation, and exceptional customer service.
  • It is the most user-friendly and customer-focused tool for implementing across our organization.
  • The staff are amazing and easy to work with.” — Customer from the Finance Industry, Company Size: $250M–$500M
    “[AlertMedia is] our favorite business partner to work with.
  • Gartner Peer Insights content consists of the opinions of individual end-users based on their own experiences and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates.

Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience

Retrieved on: 
Tuesday, February 27, 2024

Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.

Key Points: 
  • Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.
  • TH Healthcare & Life Sciences will leverage Technology Holdings 23 years of healthcare transaction expertise, global reach with a presence in 9 countries and deep healthcare and life sciences sector knowledge.
  • TH Healthcare & Life Sciences leverages decades of relationships with key healthcare strategic buyers and private equity funds with a specialized, dedicated team of healthcare investment bankers allowing TH Healthcare & Life Sciences to strategically position healthcare and life sciences businesses and continue to achieve outstanding results for its clients.
  • “We are excited to announce the launch of TH Healthcare & Life Sciences, serviced by a dedicated team of healthcare investment bankers globally across 9 countries and 5 continents.

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Retrieved on: 
Monday, February 26, 2024

IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
  • “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
    IQVIA’s full 2023 ESG report can be downloaded here .
  • We established our dedicated global public health business in 2023, which now works with more than 75 clients across the globe.
  • For the third year in a row, IQVIA was named the number one most admired company in our category, Healthcare: Pharmacy and Other Services.

Humana Announces Strategic Partnership with Veda to Improve Accuracy of Provider Directories

Retrieved on: 
Monday, February 26, 2024

Leading health and well-being company Humana Inc. (NYSE: HUM) today announced a strategic partnership with Veda , a health technology company specializing in helping healthcare companies solve complex provider data challenges.

Key Points: 
  • Leading health and well-being company Humana Inc. (NYSE: HUM) today announced a strategic partnership with Veda , a health technology company specializing in helping healthcare companies solve complex provider data challenges.
  • Humana will partner with Veda to improve the accuracy of its provider information and ensure that seniors have real-time details about in-network providers, making it easier for them to access high-quality healthcare.
  • Ensuring the accuracy of provider directories has been the source of ongoing challenges for seniors, health plans, providers and policymakers.
  • “We want to be a partner with CMS and policymakers in improving the accuracy of provider directories.

Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101

Retrieved on: 
Monday, February 26, 2024

Dravet syndrome is the most common developmental and epileptic encephalopathy and is characterized by a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation.

Key Points: 
  • Dravet syndrome is the most common developmental and epileptic encephalopathy and is characterized by a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation.
  • The UK CTA for EXPEDITION is part of a global regulatory strategy established by Encoded for clinical development of ETX101, which also includes regulatory clearance for an investigational new drug (IND) application in the United States and approval under the Clinical Trial Approval (CTA) scheme in Australia.
  • “This CTA marks the third regulatory approval for ETX101 as we advance our global clinical development program, POLARIS, to bring this potential one-time AAV gene regulation therapy to people affected by SCN1A+ Dravet syndrome around the world,” said Sal Rico, M.D., Ph.D., Chief Medical Officer of Encoded.
  • EXPEDITION represents a significant stride forward in our collective pursuit of new treatments that can truly make a difference in the lives of people affected by Dravet syndrome."